

Reference Number: FOI202425/025
From: Private Individual
Date: 11 April 2024
Subject: Biliary Tract and Non-Small Cell Lung Cancer Treatment

I would be grateful if you could please provide the following information with regards to patients treated with Durvalumab (Imfinzi) and Nivolumab.

Where the specified Nov 23 – March 24 timeframe is not possible to provide, could you please provide the latest 5 months of data you have, and specify which timeframe this covers.

- Q1 How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?
- a. Biliary Tract Cancer
 - b. Non-Small Cell Lung Cancer
- A1 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.
- Q2 How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Nivolumab for early stage (resectable) non-small cell lung cancer (Stages 1 – 3b).
- A2 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.
- Q3 How many unique total patients were treated last month (March 24) with Durvalumab for the following indications?
- a. Biliary Tract Cancer
 - b. Non-Small Cell Lung Cancer
- A3 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.
- Q4 How many patients received their first treatment in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?
- a. Biliary Tract Cancer
 - b. Non-Small Cell Lung Cancer

- A4 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.